| Literature DB >> 33367178 |
Milcheva Evelina Marinova1,2, Krasimirova Emilia Naseva3, Todorov Yani Zdravkov1,2, Stoimenov Dimitar Dabov1,2.
Abstract
Objective: To analyze therapy of glaucoma among the elderly population, 65 years old and above, in Sofia city, the capital of Bulgaria.Entities:
Keywords: elderly; fixed combination; glaucoma; medication; therapy
Year: 2020 PMID: 33367178 PMCID: PMC7739016 DOI: 10.22336/rjo.2020.62
Source DB: PubMed Journal: Rom J Ophthalmol ISSN: 2457-4325
Distribution of the usage of different groups of antiglaucoma medications in mono- or combined therapies in both studies
| Group of medication | Percent, % in POSE | Percent, % in GSW |
|---|---|---|
| PGAs | 68% | 54% |
| β-Blockers | 55% | 85% |
| CAIs | 24% | 39% |
| α-2 agonists | 9% | 8% |
| No conservative therapy | 19% | 10% |
Analysis of the number of medications used to treat glaucoma
| Number of medications | Percent, % in POSE | Percent, % in GSW |
|---|---|---|
| Monotherapy | 43% | 46% |
| Two medications | 22% | 39% |
| Three medications | 10% | 8% |
| Four medications | 5% | 8% |
Number of containers of eye drops used by the patients
| Number of containers | Percent, % in POSE | Percent, % in GSW |
|---|---|---|
| Single container | 63% | 65% |
| Two containers | 15% | 12% |
| Three containers | 3% | 0% |
Correlation between the number of active substances and the number of containers of eye drops
| Number of medications *Number of containers | |||
|---|---|---|---|
| Number of medications | Number of containers | ||
| 1 | 2 | 3 | |
| Monotherapy | 100% | 0% | 0% |
| Two medications | 86% | 14% | 0% |
| Three medications | 0% | 100% | 0% |
| Four medications | 0% | 40% | 60% |
| Total | 78% | 19% | 4% |
Usage of different groups of antiglaucoma drugs in mono and combined therapies
| Group of medication | Number of drugs used | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| No β-blockers | 31% | 3% | 0% | 0% |
| β-blockers | 30% | 41% | 20% | 9% |
| No PGAs | 21% | 8% | 0% | 0% |
| PGAs | 44% | 30% | 18% | 8% |
| No CAIs | 36% | 14% | 1% | 0% |
| CAIs | 4% | 33% | 42% | 21% |
| No α-2 agonists | 32% | 17% | 7% | 0% |
| α-2 agonists | 11% | 22% | 11% | 56% |